What does this research mean for the field?

Radical radiotherapy to the prostate and all oligometastatic sites significantly improves 5-year progression-free survival compared to prostate radiotherapy alone in patients with de novo low-burden metastatic hormone-sensitive prostate cancer. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

This study aims to compare the outcomes of radical radiotherapy versus prostate radiotherapy alone in patients with de novo low-burden metastatic hormone-sensitive prostate cancer.

May 29, 2026Journal of Clinical Oncology

Outcomes of radical radiotherapy in de novo low-burden metastatic hormone-sensitive prostate cancer vs prostate radiotherapy alone.

View Full Paper

Ask AI

Bookmark

Authors

KYKelvin YanChinese University of Hong Kong CYCarson YipChinese University of Hong Kong FMFrankie MoChinese University of Hong Kong

Discussion

Member takes

Implication

Randomized trial compares radical radiotherapy outcomes in low-burden metastatic prostate cancer, suggesting better survival benefits.

Key Points

This study aims to compare the outcomes of radical radiotherapy versus prostate radiotherapy alone in patients with de novo low-burden metastatic hormone-sensitive prostate cancer.
Reviewed patients with de novo low-burden metastatic hormone-sensitive prostate cancer receiving radical radiotherapy (Arm A) or prostate radiotherapy alone (Arm B).
Analyzed progression-free survival, overall survival, and treatment-related toxicity using Kaplan-Meier and Cox-proportional hazards models.
Included 127 eligible patients from a Hong Kong tertiary hospital between January 2012 and January 2023.
5-year progression-free survival was significantly better in Arm A (86.1%) compared to Arm B (50.3%), P=0.0173, HR 0.213, 95% CI 0.059-0.761.
Median follow-up was 40.2 months in Arm A and 30.3 months in Arm B.
No differences in treatment-related toxicities between the two treatment arms.

Cite This Study

Yan et al. (2026) studied this question.

synapsesocial.com/papers/6a192ee7fab5b468c441828a https://doi.org/10.1200/jco.2026.44.16_suppl.5097

View Full Paper

Ask AI

Bookmark

Outcomes of radical radiotherapy in de novo low-burden metastatic hormone-sensitive prostate cancer vs prostate radiotherapy alone.

Discussion

Member takes

Implication

Key Points

Cite This Study

Outcomes of radical radiotherapy in de novo low-burden metastatic hormone-sensitive prostate cancer vs prostate radiotherapy alone.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider